Interleukin 25

IL-25 and IL-17 family

IL-25 is a cytokine that belongs to the IL-17 cytokine family together with IL-17A (named also IL-17), IL-17B, IL-17C, IL-17D and IL-17F. This is why IL-25 has the alternative name IL-17E. All members have homologous amino acid sequence segments and spatially conserved cysteines. It is the IL-25 that differs from other members in its function and structure.

IL-25 signals through a heterohexameric receptor complex containing IL-17RA and IL-17RB. In this complex, IL-25 forms a homodimer with IL-17RB, which then binds to IL-17RA. The IL-17RA subunit is common for IL-17A and IL-17F, and IL-17RB is common for IL-17B. Both IL-17RA and IL-17RB are essential for IL-25 functions. IL-25 does not bind directly to IL-17RA, but this subunit is necessary for its functions - as well as IL-17RB which directly bind IL-25.

Function

IL-25 is produced by many cell types. These cells include T cells, dendritic cells, macrophages, mast cells, basophils, eosinophils, epithelial cells and Paneth cells.

This cytokine can induce NF-κB activation, and stimulate the production of IL-8 (named also CXCL8), which is the major chemotactic substance of neutrophils.

Another important function of interleukin 25 is to support the Th2 immune response. IL-25 has been shown to induce the production of IL-4, IL-5 and IL-13. Evidence is the expression of IL-17RB on Th2 cells, not on Th1 and Th17. In addition, IL-25 is responsible for the decrease in IFN gamma.

Because IL-25 promotes the development of a Th2 immune response, it acts to protect against several bowel infections caused by helminths. This role of IL-25 has been demonstrated in these intestinal parasites - Nippostrongylus brasiliensis , Trichuris muris , Trichinella spiralis and Heligmosomoides polygyrus bekeri.

IL-25 is also referred to as the regulator of IL-9 production. IL-25 has been shown to increase the production of IL-9 in Th9 cells. Th9 cells can arise not only from naive T cells but also from differentiated Th2 cells.

Another function of IL-25 is the activation of natural lymphoid cells 2 (ILC2). IL-25 and IL-33 are the most potent activators of ILC2.

Clinical significance

IL-25 induces the production of other cytokines, including IL-4, IL-5 and IL-13 in multiple tissues, which stimulate the expansion of eosinophils. This cytokine is an important molecule controlling immunity of the gut and has been implicated in chronic inflammation associated with the gastrointestinal tract. IL-25 can kill some types of breast cancer cells.

Further, the IL-25 gene has been identified in a chromosomal region associated with diseases of the gut such as inflammatory bowel disease (IBD), although no direct evidence suggests that IL-25 plays any role in this disease.

IL-25 has potent antitumor activity in vivo in several human cancers including melanoma, breast, lung, colon, and pancreatic cancers, suggesting the potential clinical use of IL-17E as an anticancer agent.

IL-25 and allergy

IL-25 works pathologically in allergies. It is a cytokine that supports the Th2 response. IL-25 induces IL-4, IL-5 a IL-13, cytokines which play important role in allergies.

Many studies suggest that blocking IL-25 activity might be useful in the treatment of allergies. Research studies suggest the blocking of IL-25 activity by the neutralizing antibody against IL-25. A delayed Th2 differentiation and delayed production of cytokines IL-4, IL-5 and IL-13 have been demonstrated in the IL-25 knockout mouse.

IL-25 influences the development of nasal polyps, and may also be involved in the etiology of chronic rhinitis with nasal polyps. A 2018 study found that after using a non-neutralizing antibody against IL-25, IL-4, IL-5, and IL-13 decreased, and the number of nasal polyps decreased.

Another proposed option of treating allergies with IL-25 is a combination of neutralizing antibodies against IL-25, IL-33 and TSLP (thymic stromal lymphopoietin). All three of these cytokines support the Th2 immune response.

References

References

1. [http://www.ebioscience.com/knowledge-center/antigen/il-17e-il-25-overview.htm Product reference for IL-17E]
2. "Entrez Gene: IL25 interleukin 25".
3. (January 2001). "IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1". The Journal of Biological Chemistry.
4. (April 2003). "Interleukin-17 family and IL-17 receptors". Cytokine & Growth Factor Reviews.
5. (September 2022). "Organizing structural principles of the IL-17 ligand-receptor axis". Nature.
6. (September 2008). "Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities". Journal of Immunology.
7. (April 2015). "Interleukin-17B Antagonizes Interleukin-25-Mediated Mucosal Inflammation". Immunity.
8. (February 2011). "Functional specialization of interleukin-17 family members". Immunity.
9. (December 2013). "IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases". Cellular Signalling.
10. (July 2007). "Interleukin 25 promotes the initiation of proallergic type 2 responses". The Journal of Experimental Medicine.
11. (December 2016). "Critical Role for Interleukin-25 in Host Protective Th2 Memory Response against Heligmosomoides polygyrus bakeri". Infection and Immunity.
12. (October 2013). "Interleukin-25 (IL-25) promotes efficient protective immunity against Trichinella spiralis infection by enhancing the antigen-specific IL-9 response". Infection and Immunity.
13. (March 2010). "Regulation of IL-9 expression by IL-25 signaling". Nature Immunology.
14. (February 2013). "Innate lymphoid cells--a proposal for uniform nomenclature". Nature Reviews. Immunology.
15. (April 2010). "Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity". Nature.
16. (April 2006). "Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract". The Journal of Experimental Medicine.
17. (October 2003). "The interleukin-25 gene located in the inflammatory bowel disease (IBD) 4 region: no association with inflammatory bowel disease". European Journal of Immunogenetics.
18. (June 2010). "IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo". Cancer Immunology, Immunotherapy.
19. (December 2001). "IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo". Immunity.
20. (May 2016). "Interleukin (IL)-25: Pleiotropic roles in asthma". Respirology.
21. (April 2006). "Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion". The Rockefeller University Press.
22. (2018). "Interleukin-25 and eosinophils progenitor cell mobilization in allergic asthma". Clinical and Translational Allergy.
23. (January 2018). "Prevention of food allergy development and suppression of established food allergy by neutralization of thymic stromal lymphopoietin, IL-25, and IL-33". The Journal of Allergy and Clinical Immunology.